Checkpoint Therapeutics, Inc. Announces Formation of Scientific Advisory Board
March 01, 2021 at 08:30 am EST
Share
Checkpoint Therapeutics, Inc. announced the formation of an independent Scientific Advisory Board comprising leaders in the fields of immunotherapy, lung and skin cancers. The Scientific Advisory Board will work closely with Checkpoint leadership to further develop Checkpoint's novel treatments for patients with solid tumor cancers, including cosibelimab and CK-101. Members of the Checkpoint Scientific Advisory Board include: Wayne A. Marasco, M.D., Ph.D. - Professor of Medicine at Harvard Medical School, Professor of Cancer Immunology and Virology at the Dana-Farber Cancer Institute. Dr. Marasco’s research group focuses on the treatment of emerging infectious diseases and cancer. To greatly expand the use of human monoclonal antibodies in the treatment of cancer, Dr. Marasco founded the National Foundation of Cancer Research Center for Therapeutic Antibody Engineering. Dr. Marasco serves as Chairman of the Checkpoint Scientific Advisory Board. F. Stephen Hodi, Jr., M.D. - Director of the Melanoma Center and the Center for Immuno-Oncology at Dana-Farber/Brigham and Women's Cancer Center and Professor of Medicine at Harvard Medical School. Dr. Hodi’s research focuses on gene therapy, the development of immune therapies, and first into human studies for malignant melanoma. Dr. Hodi is a member of the American Society of Clinical Oncology (ASCO), the Eastern Cooperative Oncology Group Melanoma Committee, the International Society for the Biological Therapy of cancer, and a founding member of the Society for Melanoma Research. Bruce E. Johnson, M.D. - Professor of Medicine at Harvard Medical School, Professor of Medicine and Adult Oncology at the Dana-Farber Cancer Institute. Dr. Johnson currently leads the Dana-Farber/Harvard Cancer Center Lung Cancer Program and is the Chief Clinical Research Officer at the Dana-Farber Cancer Institute. Dr. Johnson was elected and served as President of the American Society for Clinical Oncology (ASCO) for the 2017-2018 term. David Miller, M.D., Ph.D. - Instructor in Dermatology and Medicine at Harvard Medical School and member of the Department of Dermatology and the Department of Medicine at Massachusetts General Hospital, where he is Director of the Center for Merkel Cell Carcinoma and co-Director of the MGH-MEEI Non-Melanoma Skin Cancer Multi-Disciplinary Clinic. Dr. Miller's research is focused on developing novel therapies for advanced skin cancer. Dr. Miller is one of the very few clinicians in the country who is board certified in Internal Medicine, Dermatology and Medical Oncology. Emily Ruiz, M.D., M.P.H. - Associate Physician at the Mohs and Dermatologic Surgery Center at Dana-Farber/Brigham and Women’s Cancer Center, an Assistant Professor of Dermatology at Harvard Medical School and Director of the High-Risk Skin Cancer Clinic at Dana Farber/Brigham and Women’s Hospital. Dr. Ruiz’s research focuses on the burden of skin cancer through health services research and non-melanoma skin cancer outcomes studies.
Checkpoint Therapeutics, Inc. is a clinical-stage immunotherapy and targeted oncology company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers. The Company is evaluating its lead antibody product candidate, cosibelimab, a potential best-in-class anti-programmed death-ligand 1 (PD-L1) antibody licensed from the Dana-Farber Cancer Institute, as a potential new treatment for patients with selected recurrent or metastatic cancers, including metastatic and locally advanced cutaneous squamous cell carcinoma. The Company is also evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer. Its anti-GITR monoclonal antibody, CK-302, is a fully human agonistic antibody that is designed to bind to and trigger signaling in GITR expressing cells.
CHECKPOINT THERAPEUTICS, INC. 
